


PROGRAM

9:00	Welcome - Peter Scammells	
9:15	Keynote speaker Chris Porter	Development of the Glyph® lymphatic targeting technology: a MIPS research story 15 years in the making
10:00	**Therapeutic Program Areas (TPAs)** **Chair: Emma Watson**	
12-min	Ben Boyd	Long Acting Injectables for Global Health applications
	Emily Reeve	SUPPORT-Meds: SUpporting Primary care Practice through Outreach, Resources and Training to optimise Medicine use
	Nik Veldhuis	Looking for analgesic targets in a rare painful skin disorder
3-min	Stanley Xie	Novel small-molecule inhibitor strategies for next-generation anti-infectives
	Aimee Freeburn	Psilocybin-assisted Psychotherapy for Depression: What Guidance Exists as Clinical Use Expands? Findings from a Rapid Review
	Anh TN Nguyen	Unlocking CaMK4: AI-guided discovery of inhibitors for profound autism
	Amanda Cross	Knowledge Broker-led Implementation of Psychotropic Guidelines in Residential Aged Care
	Liam Koehn	Inter-alpha inhibitor proteins in the context of motor neurone disease
	Abisola Siedoks	Novel Peptide-Based Inhibitors of Protein Kinase Cε Interactions for the Treatment of Type 2 Diabetes Mellitus
	Alene Yong	Stakeholder Perspectives on Implementing Psilocybin-Assisted Psychotherapy
11:00	**Morning Tea**	
11:30	**Tech Development & Translation** **Chair: Tracy Josephs**	
12-min	Martin Scanlon	X-ray crystallographic fragment screening (CFS) platform for accelerating fragment-based drug discovery (FBDD) in Australia
	Manuela Jorg	Electrochemical β-lactam probes for rapid detection of β-lactamases
3-min	Maxim Gongalsky	A Luminescent Porous Silicon Biosensor for Protease Activity Sensing toward Infection Monitoring
	Brooke Blakeley	The effectiveness of knowledge brokers and a national quality improvement collaborative for implementing national principles for medication management
	Nileshni Fernando	Co-designing resources to support medication management of urinary incontinence for people with dementia
12:05	**EMCR Spotlight** **Chair: Rehan Sarwar**	
12-min	Arisbel Batista Gondin	Amplifying Endogenous GPCR Signalling
	Matthew Rowe	Multiplex fluorescent immunostaining reveals GC numbers and mucus characteristics are altered in Hirschsprung disease

3-min	Sanduni Madawala	Targeting treatable traits in COPD in primary care: Findings from the TERRACOTTA cluster randomised controlled trial
	Jack McDonald	A closer look at GPR17 antagonists for remyelination
	Kate Fincham	Enhancing the Cytosolic Delivery of Peptide Inhibitors
	Siobhonne Breen	Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates
	Gopisankar Mohanannair Geethadevi	Utility of a Consolidated Multimodal Report for Neurologists Treating Adults with Seizures
	William De Nardo	Modulating mRNA-LNP antigen presentation decouples B and T cell responses to shape durable immunity
12:50	**Lunch**	
13:50	**Faculty-Wide Research** **Chair: Peter Scammells**	
12-min	Jenni Ilomaki	Secondary prevention after myocardial infarction in people with dementia: Is more always better?
	David Thal	Seeing is believing: why prediction still needs the experiment
	Yun Shi	Ligand and Target Discovery in NAD^+ Biology
3-min	Nick Barlow	New Generation Peptide Therapeutics
	Anna Mackintosh	Identifying Trial-Ready Prescribing Indicators
	Shin Liau	Developing guiding principles to support the integration of deprescribing recommendations in clinical practice guidelines
	Jann Harberts	Less Is More: Surface Chemistry Shapes Nanoinjection Efficiency
14:45	**EMCR Spotlight** **Chair: Anouk Becker**	
12-min	Andrea Chan, Kai Kikuchi, & Josh Morrow	Development of non-invasive imaging agents for the digestive lymphatic system
	Michaela Kaoullas, Jasmin Li, & Yuxiang Ren	Lymph-specific muscarinic acetylcholine receptor (mAChR) modulators to treat arthritis and lymphedema
3-min	Azadeh Nilghaz	Architecture-Dependent Nanoparticle Transport in Microfluidic BBB-on-a-Chip Models
	Aeson Chang	Tumour cells hijack sympathetic neural signalling to limit chemotherapy control of metastasis
	Rehan Sarwar	Reducing Dementia Risk in Primary Care: Findings from the HAPPI MIND Cluster Randomised Trial
	Anastasiia Artuyants	What Happens to a Lipid Droplet in the Gut?
	Adelle Gadowski	Implementing the ENGAGEMENT Trial: Early Lessons from a Multi-site Pilot for Asthma and COPD
	Ryan Keenan	Subcutaneous administration of the Kv1.3 blocking peptide HsTX1[R14A] improves cognitive performance in APP/PS1 mice
15:30	**Afternoon tea**	
16:00	**Advanced Discovery Showcase** **Chair: Jie Tang**	
15-min	Colin Pouton	mRNA technology - where are we now?
	Cameron Nowell	What's Next in Imaging: New Equipment & Strategic Partnerships
	Kieran Stockton	Bridging the gap between bench and bedside – a Monash/Children's Cancer Institute collaboration
16:45	Final Remarks - Chris Porter	
17:10	**Networking and celebration**	
19:00	End	